Freestone Capital Holdings’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $613K | Buy |
10,634
+22
| +0.2% | +$1.26K | 0.02% | 345 |
|
|
2026
Q1 | $644K | Buy |
10,612
+716
| +7% | +$41.7K | 0.02% | 306 |
|
|
2025
Q4 | $534K | Sell |
9,896
-756
| -7% | -$36.4K | 0.02% | 324 |
|
|
2025
Q3 | $480K | Sell |
10,652
-8,836
| -45% | -$413K | 0.01% | 353 |
|
|
2025
Q2 | $902K | Buy |
19,488
+3,855
| +25% | +$189K | 0.03% | 234 |
|
|
2025
Q1 | $953K | Sell |
15,633
-32,331
| -67% | -$1.88M | 0.04% | 219 |
|
|
2024
Q4 | $2.71M | Sell |
47,964
-30,906
| -39% | -$1.73M | 0.09% | 138 |
|
|
2024
Q3 | $4.08M | Buy |
78,870
+31,738
| +67% | +$1.49M | 0.14% | 111 |
|
|
2024
Q2 | $1.96M | Sell |
47,132
-9,454
| -17% | -$423K | 0.07% | 164 |
|
|
2024
Q1 | $3.07M | Sell |
56,586
-4,767
| -8% | -$243K | 0.11% | 128 |
|
|
2023
Q4 | $3.15M | Sell |
61,353
-5,188
| -8% | -$272K | 0.14% | 115 |
|
|
2023
Q3 | $3.86M | Buy |
66,541
+2,209
| +3% | +$135K | 0.2% | 84 |
|
|
2023
Q2 | $4.11M | Buy |
64,332
+307
| +0.5% | +$20.6K | 0.17% | 90 |
|
|
2023
Q1 | $4.44M | Sell |
64,025
-2,877
| -4% | -$203K | 0.2% | 80 |
|
|
2022
Q4 | $4.81M | Sell |
66,902
-17,047
| -20% | -$1.29M | 0.22% | 75 |
|
|
2022
Q3 | $5.97M | Sell |
83,949
-17,221
| -17% | -$1.25M | 0.27% | 61 |
|
|
2022
Q2 | $7.79M | Sell |
101,170
-19,017
| -16% | -$1.45M | 0.3% | 52 |
|
|
2022
Q1 | $8.78M | Sell |
120,187
-1,821
| -1% | -$122K | 0.35% | 61 |
|
|
2021
Q4 | $7.61M | Buy |
122,008
+1,460
| +1% | +$85.6K | 0.32% | 68 |
|
|
2021
Q3 | $7.13M | Buy |
120,548
+1,575
| +1% | +$104K | 0.36% | 63 |
|
|
2021
Q2 | $7.95M | Sell |
118,973
-25,059
| -17% | -$1.63M | 0.4% | 59 |
|
|
2021
Q1 | $9.09M | Sell |
144,032
-1,817
| -1% | -$113K | 0.49% | 46 |
|
|
2020
Q4 | $9.05M | Buy |
145,849
+17,245
| +13% | +$1.06M | 0.53% | 37 |
|
|
2020
Q3 | $7.75M | Buy |
128,604
+591
| +0.5% | +$35.6K | 0.51% | 41 |
|
|
2020
Q2 | $7.53M | Buy |
128,013
+8,213
| +7% | +$491K | 0.09% | 50 |
|
|
2020
Q1 | $6.68M | Sell |
119,800
-5,132
| -4% | -$314K | 0.14% | 51 |
|
|
2019
Q4 | $8.02M | Sell |
124,932
-16,835
| -12% | -$964K | 0.17% | 41 |
|
|
2019
Q3 | $7.19M | Buy |
141,767
+31,948
| +29% | +$1.5M | 0.17% | 47 |
|
|
2019
Q2 | $4.98M | Buy |
+109,819
| New | +$5.12M | 0.13% | 106 |
|
|
2018
Q1 | – | Sell |
-3,463
| Closed | -$212K | – | 339 |
|
|
2017
Q4 | $212K | Sell |
3,463
-238
| -6% | -$14.9K | 0.01% | 323 |
|
|
2017
Q3 | $236K | Buy |
+3,701
| New | +$216K | 0.02% | 308 |
|
Other funds holding BMY
Freestone Capital Holdings's BMY Position: Q2 2026 in Review
Freestone Capital Holdings increased its Bristol-Myers Squibb (BMY) stake by 0.21% in Q2 2026, buying an estimated $1.26K and bringing the position to 10,634 shares worth $613K. The position accounts for 0.02% of the portfolio, ranked #345.
Freestone Capital Holdings first reported a position in BMY in Q3 2017 and has held it in 31 quarters since. The position peaked at $9.09M in Q1 2021. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Freestone Capital Holdings held 10,634 shares of Bristol-Myers Squibb worth $613K as of Q2 2026.
- Freestone Capital Holdings bought 22 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.26K.
- Bristol-Myers Squibb made up 0.02% of Freestone Capital Holdings's portfolio in Q2 2026, its #345 holding.
- Freestone Capital Holdings first reported a position in Bristol-Myers Squibb in Q3 2017 and has held it in 31 quarters since.
- Freestone Capital Holdings's Bristol-Myers Squibb position peaked at $9.09M in Q1 2021.
- 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Freestone Capital Holdings's 13F filing for Q2 2026, filed 31 Jul 2026.